Exploratory Analyses of Efficacy Data From Major Depressive Disorder Trials Submitted to the US Food and Drug Administration in Support of New Drug Applications
The DOI matches its Crossref record.
Abstract
OBJECTIVE: There has been concern about a high rate of placebo response and a substantial failure rate in recent clinical trials in major depressive disorder (MDD). This report explores differences in efficacy data from placebo-controlled MDD trials submitted in support of new drug applications (NDAs) over a 25-year period. METHOD: We compiled efficacy data from 81 randomized, double-blind clinical trials, with 21,611 evaluable patients, that were submitted to the US Food and Drug Administration as part of NDAs for an antidepressant claim between 1983 and 2008. Trial data were limited to completed, randomized, multicenter, double-blind, placebo-controlled clinical trials in adult patients diagnosed with MDD according to DSM-III or DSM-IV criteria. The database was further limited to patients who were involved in clinical trials for drugs widely viewed as effective antidepressants and for doses of these drugs also viewed as effective doses. Trials were rated as successful if they showed statistical superiority vs placebo for the investigational drug on change in Hamilton Depression Rating Scale (HDRS) score (last-observation-carried-forward data). (Trials with multiple investigational drug groups were successful if there was superiority in at least 1 drug group after adjustment for multiplicity.) In particular, we explored differences in effect size and success rate of these trials, based on when the studies were conducted, geographic location of the study sites (US vs non-US), trial duration, dosing regimen, study size, and baseline disease characteristics. RESULTS: Eighty-one percent of MDD patients were enrolled in US sites. Although the observed placebo and drug responses at non-US sites tended to be larger than at US sites, the treatment effect (drug-placebo difference) was similar (mean change from baseline of about -2.5 units in HDRS total score) in US and non-US trials. In both US and non-US trials, the placebo response showed a modest increase over the observation period (1983-2008). Treatment effect clearly diminished over this same period, at a similar rate for both US and non-US trials despite a marked increase in the sample size of the trials. Our analysis showed that 53% of all MDD trials in the last 25 years were successful. US trials had a higher success rate than non-US trials (58% vs 33%). Before 1995, the overall success rate was 55%, compared to 50% for trials in 1995 or later, and, in general, 6-week trials had a higher success rate than 8-week trials (55% vs 42%). It should be noted that the earlier trials were mostly 6 weeks, and the 6-week trials had higher mean baseline HDRS scores than the 8-week trials. Study size did not seem to influence trial success rates. Mean baseline HDRS total scores declined over the 25-year observation period for patients in both US and non-US trials, as did treatment effect in these trials, again, regardless of region. Fixed-dose trials had a numerically slightly greater success rate than flexible-dose trials (57% vs 51%), although on average treatment effect was numerically larger in the flexible-dose trials than in fixed-dose trials (mean of -2.9 vs -2.0 on HDRS units). CONCLUSIONS: Treatment effect has declined over time in MDD trials, and there has been a high failure rate for these trials during the entire period, but the reasons for these findings remain elusive. Baseline disease severity seems to be a more important factor in study outcome than study duration, dosing regimen, sample size, time when studies were conducted, and regions where data were generated. Close attention is needed to a variety of factors in the design and conduct of these studies, including patient population, diagnostic considerations, patient assessment, and clinical practice differences. These considerations become increasingly important as globalization of clinical trials continues to increase.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The Genetics of Major Depression
Flint, J., & Kendler, K. S. (2014) · Neuron · doi:10.1016/j.neuron.2014.01.027 · Cited by 724
A meta-analysis of the use of probiotics to alleviate depressive symptoms
Ng, Q. X., Peters, C., Ho, C. Y. X., Lim, D. Y., & Yeo, W.-S. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.11.063 · Cited by 357
Esketamine for Treatment-Resistant Depression — First FDA-Approved Antidepressant in a New Class
Kim, J., Farchione, T., Potter, A., Chen, Q., & Temple, R. (2019) · New England Journal of Medicine · doi:10.1056/nejmp1903305 · Cited by 333
Undurraga, J., & Baldessarini, R. J. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.306 · Cited by 269
Depression and Survival in Metastatic Non–Small-Cell Lung Cancer: Effects of Early Palliative Care
Pirl, W. F., Greer, J. A., Traeger, L., Jackson, V., Lennes, I. T., Gallagher, E. R., Perez-Cruz, P., Heist, R. S., & Temel, J. S. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.3166 · Cited by 228
Furukawa, T. A., Cipriani, A., Atkinson, L. Z., Leucht, S., Ogawa, Y., Takeshima, N., Hayasaka, Y., Chaimani, A., & Salanti, G. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30307-8 · Cited by 219
Placebo effect in the treatment of depression and anxiety
Kirsch, I. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00407 · Cited by 205
Dowrick, C., & Frances, A. (2013) · BMJ · doi:10.1136/bmj.f7140 · Cited by 167
Antidepressants and the placebo effect
Kirsch, I. (2014) · Zeitschrift für Psychologie · doi:10.1027/2151-2604/a000176 · Cited by 164
“The FDA even did its own meta-analysis on all of the antidepressants that they have approved (Khin et al., 2011).”
BackgroundTreating major depression with yoga: A prospective, randomized, controlled pilot trial
Prathikanti, S., Rivera, R., Cochran, A., Tungol, J. G., Fayazmanesh, N., & Weinmann, E. (2017) · PLOS ONE · doi:10.1371/journal.pone.0173869 · Cited by 157
Layous, K., Chancellor, J., Lyubomirsky, S., Wang, L., & Doraiswamy, P. M. (2011) · The Journal of Alternative and Complementary Medicine · doi:10.1089/acm.2011.0139 · Cited by 148
Tabuteau, H., Jones, A., Anderson, A., Jacobson, M., & Iosifescu, D. V. (2022) · American Journal of Psychiatry · doi:10.1176/appi.ajp.21080800 · Cited by 140
Sanacora, G., Johnson, M. R., Khan, A., Atkinson, S. D., Riesenberg, R. R., Schronen, J. P., Burke, M. A., Zajecka, J. M., Barra, L., Su, H.-L., et al. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.224 · Cited by 120
“…separation between placebo and active antidepressant medications in more severely depressed subjects (Khan et al, 2011; Fournier et al, 2010, 2010; Khin et al, 2011; Naudet et al, 2011), we found evidence that baseline severity impacted drug and placebo responses, with the most severely depressed…”
BackgroundMechanisms of antidepressant resistance
El-Hage, W., Leman, S., Camus, V., & Belzung, C. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00146 · Cited by 111
Thombs, B. D., Ziegelstein, R. C., Roseman, M., Kloda, L. A., & Ioannidis, J. P. (2014) · BMC Medicine · doi:10.1186/1741-7015-12-13 · Cited by 100
“These factors have been discussed in detail elsewhere [3], but include the already high rate of antidepressant use in primary care settings [33,34]; the likely overestimation in the research literature of the accuracy of depression screening tools for identifying previously unrecognized cases of depression [35]; and t…”
BackgroundPharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder
Alvarez, E., Artigas, F., & Perez, V. (2014) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s41387 · Cited by 84
Mahableshwarkar, A. R., Jacobsen, P. L., Serenko, M., Chen, Y., & Trivedi, M. H. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09337 · Cited by 84
Self-citationThe Genetics of Major Depression
Flint, J., & Kendler, K. S. (2014) · Neuron · doi:10.1016/j.neuron.2014.02.033 · Cited by 81
“There is even dispute about the value of medication (Khin et al., 2011; Kirsch et al., 2008; Turner et al., 2008; Vöhringer and Ghaemi, 2011) and psychological therapies (Cuijpers et al.”
Ratti, E., Bettica, P., Alexander, R., Archer, G., Carpenter, D., Evoniuk, G., Gomeni, R., Lawson, E., Lopez, M., Millns, H., et al. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113480990 · Cited by 69
“This is at the upper end of the range for drug-placebo differences observed in recent depression studies as reported in a 2011 FDA meta-analysis of antidepressant trials (Khin et al., 2011), and somewhat larger than the 1.”
ResultInfluentialTakahashi, N., Yamada, A., Shiraishi, A., Shimizu, H., Goto, R., & Tominaga, Y. (2021) · BMC Psychiatry · doi:10.1186/s12888-021-03538-y · Cited by 57
Sugarman, M. A., Loree, A. M., Baltes, B. B., Grekin, E. R., & Kirsch, I. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106337 · Cited by 55
Gommoll, C. P., Greenberg, W. M., & Chen, C. (2014) · Journal of Drug Assessment · doi:10.3109/21556660.2014.884505 · Cited by 43
“Khan et al.37,38 reported success rates of 59.6% for MDD trials with a flexible-dose design vs 31.4% for fixed-dose trials; conversely, an analysis by Khin et al.35 found a slightly higher success rate in fixed-dose (57”
ResultInfluentialAligning physiology with psychology: Translational neuroscience in neuropsychiatric drug discovery
McArthur, R. A. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.02.004 · Cited by 42
The conundrum of depression clinical trials: one size does not fit all
Khan, A., Mar, K. F., & Brown, W. A. (2018) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000229 · Cited by 30
“…of trial designs and techniques that appeared promising for containing the placebo response have not been shown to be effective, and recent reports (Khin et al., 2011; Khan et al., 2017) failed to identify any association of these design features with the increase in placebo response.”
BackgroundWarren, J. B. (2020) · BMJ · doi:10.1136/bmj.m3200 · Cited by 30
Furukawa, T. A., Salanti, G., Cowen, P. J., Leucht, S., & Cipriani, A. (2020) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13145 · Cited by 26
“More recent reports, however, have not found such a difference between the two types of clinical studies (17, 18).”
ResultWhat the alcohol doctor ordered from the neuroscientist
Heilig, M., & Leggio, L. (2016) · Progress in Brain Research · doi:10.1016/bs.pbr.2015.07.023 · Cited by 25
(2014) · Europe PMC (PubMed Central) · Cited by 24
The antidepressant standoff: Why it continues and how to resolve it
Ormel, J., Spinhoven, P., de Vries, Y. A., Cramer, A. O. J., Siegle, G. J., Bockting, C. L. H., & Hollon, S. D. (2020) · Psychological Medicine · doi:10.1017/s0033291719003295 · Cited by 22
Comment on a Word to the Wise About Intranasal Esketamine
Drevets, W. C., Singh, J. B., Hough, D., Daly, E. J., Popova, V., & Manji, H. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19070688 · Cited by 12
The current state-of-the-art in pharmacotherapy for pediatric generalized anxiety disorder
Castagna, P. J., Farahdel, E., Potenza, M. N., & Crowley, M. J. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2199921 · Cited by 3
Metadata
- Authors
- Khin, N. A., Chen, Y.-F., Yang, Y., Yang, P., & Laughren, T. P.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2011-04-15
- Volume
- 72
- Issue
- 04
- Pages
- 464-472
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2071735605
- Cited by
- 212
- References
- 0
- FWCI
- 14.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.